<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BPR0L075 [6-<z:chebi fb="8" ids="32772">methoxy</z:chebi>-3-(3',4',5'-trimethoxy-<z:chebi fb="3" ids="22733">benzoyl</z:chebi>)-1H-<z:chebi fb="0" ids="35581">indole</z:chebi>] is a novel anti-microtubule drug with anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and anti-angiogenic activities in vitro and in vivo </plain></SENT>
<SENT sid="1" pm="."><plain>Securin is required for genome stability, and is expressed abundantly in most <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells, promoting cell proliferation and <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we found that BPR0L075 efficiently induced cell <z:hpo ids='HP_0011420'>death</z:hpo> of HCT116 human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells that have higher expression levels of securin </plain></SENT>
<SENT sid="3" pm="."><plain>The cytotoxicity of BPR0L075 was attenuated in isogenic securin-null HCT116 cells </plain></SENT>
<SENT sid="4" pm="."><plain>BPR0L075 induced DNA damage response, G(2)/M arrest, and activation of the spindle assembly checkpoint in HCT116 cells </plain></SENT>
<SENT sid="5" pm="."><plain>Interestingly, BPR0L075 induced phosphorylation of securin </plain></SENT>
<SENT sid="6" pm="."><plain>BPR0L075 withdrawal resulted in degradation of securin, mitotic exit, and mitotic catastrophe, which were attenuated in securin-null cells </plain></SENT>
<SENT sid="7" pm="."><plain>Inhibition of cdc2 decreased securin phosphorylation, G(2)/M arrest and cell <z:hpo ids='HP_0011420'>death</z:hpo> induced by BPR0L075 </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, BPR0L075 caused cell <z:hpo ids='HP_0011420'>death</z:hpo> through a caspase-independent mechanism and activation of JNK and p38 MAPK pathways </plain></SENT>
<SENT sid="9" pm="."><plain>These findings provided evidence for the first time that BPR0L075 treatment is beneficial for the treatment of human <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> with higher levels of securin </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, we suggest that the expression levels of securin may be a predictive factor for application in anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy with BPR0L075 in human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
</text></document>